Skip to main content
Transportation Update Actualización de transporte

SafeRide Health (SRH) is the new provider for all NEMT rides to doctor appointments and pharmacy visits.

Depending on your needs, rides may include wheelchair-lift-equipped vehicles, stretcher vans, minivans, or ambulatory vans. Please let SRH know what type of ride you need when scheduling.

Learn more

SafeRide Health (SRH) es el nuevo proveedor de todos los servicios de transporte médico que no son de emergencia (NEMT, por sus siglas en inglés) hacia consultas médicas y farmacias.

Según tus necesidades, los servicios de transporte pueden incluir vehículos con elevador para sillas de ruedas, camionetas con camilla, minivans o camionetas ambulatorias. Por favor, informa a SRH qué tipo de transporte necesitas al programar tu traslado.

Obtenga más información AQUI

Conduent Incident Incidente de Conduent

COVID-19 Convalescent Plasma Benefit Modified

Date: July 5, 2022Attention: All ProvidersEffective Date: December 28, 2021Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.Call to action: On February 10, 2022, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the emergency use of COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies for the treatment of COVID-19 patients with immunosuppressive disease or receiving immunosuppressive treatment in either the inpatient or outpatient setting. Convalescent plasma treatment of hospitalized patients with COVID-19 has been subject to EUA since August of 2020. Subsequent scientific studies have indicated the need to modify this EUA by limiting use in immunocompromised patients. A new HCPCS code C9507 was created to describe this service (C9507 long descriptor: Fresh frozen plasma, high titer COVID-19 convalescent, frozen within 8 hours of collection, each unit). How this impacts providers:
  • Effective for dates of service on or after December 28, 2021, procedure code C9507 (administration of high titer COVID-19 convalescent fresh frozen plasma in the outpatient) is a benefit. Procedure code C9507 is applicable for diagnosis code U071.
  • Clients of all ages, including pregnant women and children who meet EUA criteria, may be eligible for procedure code C9507.
  • Providers must follow the National Institutes of Health COVID-19 Treatment Guidelines for convalescent plasma, which can be found on the following webpage: NIH COVID convalescent plasma guidelines.
  • Procedure code C9507 can be administered by the following providers and places of service:
 
Place of ServiceProvider Type
Outpatient HospitalAmbulatory surgical center
Outpatient HospitalHospital Providers


HHSC will cover convalescent plasma as a non-risk payment. Note: Prior authorization will not be required for procedure code C9507 in fee-for-service Next steps for providers: Prescribers should share this communication with their staff. If you have any questions, please email Provider Network Management at: providerrelations@texaschildrens.org.For access to all provider alerts,log into: www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers